Kurzfassung

A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure. The primary endpoint for this trial is to demonstrate the superior effects of Telmisartan (T) and Amlodipine (A) vs Olmesartan (O) and Hydrochlorothiazide (HCTZ) in endothelial function as measured by flow mediated dilatation after 26 weeks of treatment in hypertensive patients at risk beyond blood pressure. Key...A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure. The primary endpoint for this trial is to demonstrate the superior effects of Telmisartan (T) and Amlodipine (A) vs Olmesartan (O) and Hydrochlorothiazide (HCTZ) in endothelial function as measured by flow mediated dilatation after 26 weeks of treatment in hypertensive patients at risk beyond blood pressure. Key secondary endpoint for this trial is the change in arterial stiffness as measured by stiffness index and reflection index. And the change in the pulsewave velocity (PWV) as measured by augmentation index (AI) after following 26 weeks of treatment. Another key secondary endpoint for this trial is to investigate the effects of T and A vs O and HCTZ on echogenicity and morphology of carotid arteria as measured by the grayscale median of carotid artery plaques after 26 weeks of treatment in hypertensive patients at risk beyond blood pressure.» weiterlesen» einklappen